Innovent Biologics, Inc. (HKG:1801)
Hong Kong
· Delayed Price · Currency is HKD | Market Cap | 159.71B |
| Revenue (ttm) | 12.52B |
| Net Income (ttm) | 1.24B |
| Shares Out | 1.71B |
| EPS (ttm) | 0.74 |
| PE Ratio | 126.14 |
| Forward PE | 98.77 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 13,981,978 |
| Average Volume | 19,330,535 |
| Open | 92.35 |
| Previous Close | 95.05 |
| Day's Range | 90.60 - 94.15 |
| 52-Week Range | 28.65 - 109.10 |
| Beta | 0.21 |
| RSI | 44.92 |
| Earnings Date | Nov 27, 2025 |
About Innovent Biologics
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People’s Republic of China, the United States, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases. Its commercial stage product portfolio includes TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injec... [Read more]
Financial Performance
In 2024, Innovent Biologics's revenue was 9.42 billion, an increase of 51.82% compared to the previous year's 6.21 billion. Losses were -94.63 million, -90.79% less than in 2023.
Financial numbers in CNY Financial StatementsNews
Innovent's weight-loss drug highlights China challenge for Novo, Lilly
Innovent Biologics' newly launched weight-loss drug is making inroads in its home market of China, ramping up competition with its Western rivals as it pursues a marketing strategy that is gaining tra...
Innovent Announces Mazdutide Received Approval from China's NMPA for Glycemic Control in Adults with Type 2 Diabetes
SAN FRANCISCO and SUZHOU, China, Sept. 19, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commerciali...
Innovent's Partner Ollin Announces Clinical Updates on IBI324 (OLN324, VEGF/ANG-2)
SAN FRANCISCO and SUZHOU, China , Sept. 18, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercia...
Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the 34th EADV Congress 2025
SAN FRANCISCO and SUZHOU, China , Sept. 15, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercial...
Fangzhou and Innovent Biologics Form Strategic Alliance for AI-Powered Weight Management Solutions
SHANGHAI, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in AI-driven Internet healthcare solutions, signed a strategic partnership with Innovent B...
Innovent Announces Phase 2 Results of Tigulixostat (IBI128, XOI) in Gout Patients were ...
Innovent Announces Phase 2 Results of Tigulixostat (IBI128, XOI) in Gout Patients were Published at the 27th Asia-Pacific League of Associations for Rheumatology Congress | IVBIY Stock News
Innovent Announces Phase 2 Results of Tigulixostat (IBI128, XOI) in Gout Patients were Published at the 27th Asia-Pacific League of Associations for Rheumatology Congress
SAN FRANCISCO and SUZHOU, China , Sept. 7, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercial...
Innovent Biologics estimates ~50% jump in 2025 revenue
Innovent Biologics reports interim results
Innovent Announces 2025 Interim Results and Business Updates
Robust revenue growth and substantial profit improvement Continued exceptional executions under a clear roadmap of dual-driven growth and global innovation SAN FRANCISCO and SUZHOU, China , Aug. 27, 2...
Innovent Biologics Announces U.S. FDA IND Approval for the First Global MRCT Phase 3 Study ...
Innovent Biologics Announces U.S. FDA IND Approval for the First Global MRCT Phase 3 Study (MarsLight-11) of IBI363 (PD-1/IL-2?-bias) in Squamous Non-Small Cell Lung Cancer | IVBIY Stock News
Innovent Biologics Announces U.S. FDA IND Approval for the First Global MRCT Phase 3 Study (MarsLight-11) of IBI363 (PD-1/IL-2α-bias) in Squamous Non-Small Cell Lung Cancer
SAN FRANCISCO and SUZHOU, China , Aug. 24, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company committed to developing, manufacturing and ...
Innovent Receives U.S. FDA Approval for IND Application of Oral GLP-1R Agonist IBI3032
SAN FRANCISCO and SUZHOU, China , Aug. 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializ...
Nature Medicine Published Phase 1 Results of Innovent Biologics' Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
SAN FRANCISCO and SUZHOU, China, July 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializ...
‘China’s Ozempic’ pioneer inks deal with JD Health for online distribution
Innovent Biologics, the first Chinese company to win regulatory approval to sell a GLP-1 drug for weight loss and diabetes, will leverage JD Health’s online distribution network as it seeks to grab a ...
Novo Nordisk, Eli Lilly face first major obesity drug rival in China as Innovent gains approval for mazdutide
Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms
SAN FRANCISCO and SUZHOU, China , June 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercial...
Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China's NMPA for Chronic Weight Management
SAN FRANCISCO and SUZHOU, China, June 27, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializ...
Innovent announces the Phase 3 Clinical Study DREAMS-1 of Mazdutide in China were Orally Presented at ADA 85th Scientific Sessions
SAN FRANCISCO and SUZHOU, China , June 24, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercialize...
Neutral On Innovent Biologics: Hard To Justify Its Premium
Innovent Biologics is pivoting to R&D and oncology growth in China, but high valuation and risks temper upside. Read why IVBXF stock is a hold.
Multiple Research Results from Innovent's General Biomedicine Pipeline to be Showcased at the ADA 85th Scientific Sessions
SAN FRANCISCO and SUZHOU, China , June 21, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercial...
Innovent Announces Completion of First Participant Dosed in the Seventh Phase 3 Clinical Trial (GLORY-OSA) of Mazdutide in China
SAN FRANCISCO and SUZHOU, China , June 15, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercialize...
Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the ADA's 85th Scientific Sessions
SAN FRANCISCO and SUZHOU, China , June 12, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commerciali...
Innovent's IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) Receives Second NMPA Breakthrough Therapy Designation for Immuno-resistant Squamous Non-Small Cell Lung Cancer
SAN FRANCISCO and SUZHOU, China , June 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commerciali...
Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Renal Cell Carcinoma
SAN FRANCISCO and SUZHOU, China, June 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercialize...